FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests

• The FDA said it will now review only a small number of emergency use authorization (EUA) requests for COVID-19 diagnostic tests.

• The agency encourages developers of all test types interested in marketing authorization to pursue authorization through the de novo classification or 510(k) clearance premarket review pathways.

• It said companies seeking EUA for their COVID tests would have to apply for the agency's traditional premarket review process.

• Also Read: No More Free COVID-19 At-Home Tests, Federal Government Says

• "Taking into account the current status of manufacturing capacity and consumer access...shifting to traditional premarket review would best meet the public health needs at the current stage of the COVID-19 public health emergency," FDA official Jeff Shuren said in a statement.

• To date, more than 430 different COVID-19 tests have been issued EUAs.

• FDA intends to focus its review on EUA and supplemental requests for tests that employ new technologies, new variants, or tests funded by a federal agency.

• The World Health Organization (WHO) also warned that it struggles to identify and track new COVID variants as governments roll back the testing.

See more from Benzinga

• Moleculin Biotech's Potential Antiviral Compound Selected For NIAID-Funded Animal Studies

• Novavax Says Initial 1M Doses Of Nuvaxovid COVID-19 Vaccine Are Available In UK

• Desantis Calls Trump 'A Moron Who Has No Business Running For President,' Former Staffers Say: Report

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.